Andrew Hamer
Net worth: 817 335 $ as of 31/05/2026
Net worth: 817 335 $ as of 31/05/2026
Andrew Hamer is Chief Medical Officer, Head-Research & Development at Cardiol Therapeutics, Inc. since 2021.
Formerly, Dr. Hamer was Executive Director-Global Development at Amgen, Inc. from 2018 to 2021.
Dr. Hamer was Vice President-Medical Affairs at Capricor Therapeutics, Inc. from 2013 to 2015 and also held the position of Vice President-Medical Affairs at Capricor, Inc. Dr. Hamer completed undergraduate education at the University of Otago.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 03/12/2025 | 669,947 ( 0.6% ) | 817 335 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 29/03/2021 |
| Companies | Position | End |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 01/03/2021 |
| CAPRICOR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30/07/2015 |
Capricor, Inc.
Capricor, Inc. BiotechnologyHealth Technology Provides cardiac stem cell therapeutics biotechnology services | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Capricor, Inc.
Capricor, Inc. BiotechnologyHealth Technology Provides cardiac stem cell therapeutics biotechnology services | Health Technology |
University of Otago
University of Otago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of cardiovascular diseases | Health Technology |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Select your edition
All financial news and data tailored to specific country editions